Korean Pharmacological Treatment Guideline for Child-Adolescent Depression: The Efficacy and Choice of Antidepressant.
- Author:
Hoo Rim SONG
1
;
Young Hwa LEE
;
Sujin YANG
;
Ji Young LEE
;
Jeong Won JANG
;
Sona JEONG
;
Hyunsuk JEONG
;
Sun Jin JO
;
Hyeon Woo YIM
;
So Young LEE
;
Tae Youn JUN
Author Information
1. Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. tyjun@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Depression;
Child;
Adolescent;
Pharmacological treatment;
Antidepressant
- MeSH:
Adolescent;
Antidepressive Agents;
Child;
Citalopram;
Cognitive Therapy;
Delivery of Health Care;
Depression*;
Fluoxetine;
Humans;
Paroxetine;
Peer Review;
Serotonin;
Sertraline;
Venlafaxine Hydrochloride
- From:Korean Journal of Psychopharmacology
2014;25(4):175-185
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The purpose of this guideline was to suggest recommendations for appropriate use of antidepressants in the child-adolescent depression. The differences of efficacy among antidepressants were evaluated. METHODS: Four kinds of reliable guidelines for the treatments of child-adolescent depression had been selected, and evidences and recommendations were extracted by the executive committee under the peer review. All the process was applied to the Manual for Guideline Adaptation version 2.0 by National Evidence-based Healthcare Collaborating Agency. RESULTS: Selective serotonin reuptake inhibitor (SSRI) could be considered for the treatments of moderate to severe child-adolescent depression. Among SSRIs, fluoxetine, sertraline, and escitalopram were recommended as having antidepressant efficacy compared with placebo, while paroxetine, venlafaxine, and tricyclic antidepressant were not recommended owing to lack of evidence. Another recommendation was to use combined treatment with cognitive behavioral therapy. CONCLUSION: This guideline, which was made through former and strict process of guideline adaptation, would contribute toward improving the quality of child-adolescent depression treatment by providing useful recommendations for the choice of antidepressant.
